Related references
Note: Only part of the references are listed.ASBMR 31st Annual Meeting MO0001-MO0445
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
Astrid K. Stunes et al.
BMC ENDOCRINE DISORDERS (2011)
Fibrates, Glitazones, and Peroxisome Proliferator-Activated Receptors
Fanny Lalloyer et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Cellular mechanisms of bone remodeling
Erik Fink Eriksen
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2010)
Osteoclasts Have Multiple Roles in Bone in Addition to Bone Resorption
Brendan F. Boyce et al.
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION (2009)
PPARδ in humans: genetic and pharmacological evidence for a significant metabolic function
Fredrik Karpe et al.
CURRENT OPINION IN LIPIDOLOGY (2009)
Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
Robert R. Henry et al.
LANCET (2009)
Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPAR gamma agonist pioglitazone
Unni Syversen et al.
BMC ENDOCRINE DISORDERS (2009)
The PPARgamma-selective ligand BRL-49653 differentially regulates the fate choices of rat calvaria versus rat bone marrow stromal cell populations
Takuro Hasegawa et al.
BMC DEVELOPMENTAL BIOLOGY (2008)
Normal Bone Anatomy and Physiology
Bart Clarke
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: A randomized, placebo-controlled trial
Dorte Glintborg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women:: A randomized, controlled trial
Andrew Grey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARα agonists.: 1.: Discovery of a novel series of potent HDLc raising agents
Michael L. Sierra et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (α/γ) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy
DM Kendall et al.
DIABETES CARE (2006)
PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors
T Akune et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone)
V Sottile et al.
CALCIFIED TISSUE INTERNATIONAL (2004)
Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts
SM Jackson et al.
FEBS LETTERS (2000)
Share Paper
